3 Result(s)

Article

Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”

Azmi Nasser, Joseph T. Hull, Tesfaye Liranso, Nicholas Fry, Andrew J. Cutler… in CNS Drugs (2022)

Article

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder is a neurodevelopmental disorder that typically begins in childhood and often persists into adulthood. Recent phase III trials have demonstrated the efficacy and safety...

Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi, Tesfaye Liranso… in CNS Drugs (2022)

Article

Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study

Psychostimulants remain first-line treatment options for the management of attention-deficit/hyperactivity disorder (ADHD). A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio...

Sharon B. Wigal, Earl Nordbrock, Akwete L. Adjei, Ann Childress… in CNS Drugs (2015)